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Abstract 
Objectives:This study aimed to determine the usefulness of the combination of 
severalelectrocardiographic (ECG) markerson risk assessment of ventricular fibrillation 
(VF) in patients withBrugadasyndrome (BrS). 
Background:Detection of high/low-risk BrSpatientsusing a noninvasive method is 
animportant issuein the clinical setting. Several ECG markers related to depolarization 
and repolarization abnormalities have been reported, butthe relationship and usefulness 
of these parametersin VF events are unclear. 
Methods:Baseline characteristics of 246 consecutive patients (236 males; mean age, 
47.6±13.6 years) with Brugada type ECG, including 13 patients witha history of VF and 
40 patients with ahistory of syncopalepisodes,were retrospectively analyzed. During the 
mean follow-up period of 45.1 months, VFin 23 patients and sudden cardiac 
death(SCD) in one patientwere observed. Clinical/geneticand electrocardiographic 
parameterswere compared with VF/SCD events. 
Results:Byunivariate analysis, history of VF, history of syncopal episodes, paroxysmal 
atrial fibrillation , spontaneous type1 pattern in the precordial leads, ECG markers of 
depolarization abnormalities(PQ >200ms, QRS duration ≥120ms,and fragmented QRS 
[f-QRS]),and those of repolarizationabnormalities(infero-lateral early repolarization 
[ER] pattern and QT prolongation)were associated with later cardiac events. By 
multivariable analysis,history of VF, history of syncopal episodes, infero-lateral ER 
pattern,f-QRS wereindependent predictors of documented VF and SCD (odds ratio, 
19.61, 28.57, 2.87, and 5.21, respectively, P<0.05). Kaplan-Meier curves showed thatthe 
presence/absence ofinfero-lateral ER and f-QRS provided a worse/better prognosis 
(log-rank test, P<0.01). 
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Conclusions:The combination of depolarization and repolarization abnormalitiesin 
BrSis associated with later VF events. The combination of these abnormalities is useful 
for detecting high-and low-riskBrSpatients. 
 
Keywords: Brugada syndrome, fragmented QRS, early repolarization, ventricular 
fibrillation, noninvasive risk assessment 
 
Abbreviations: 
 BrS: Brugada syndrome 
 ECG: electrocardiogram 
 EP: electrophysiology 
       ER: early repolarization 
 f-QRS: fragmented QRS 
 ICD: implantable cardioverter defibrillator 
       PAF: paroxysmal atrial fibrillation 
SCD: sudden cardiac death 
SCN5A: pore-forming region of the human cardiac sodium channel 
VF: ventricular fibrillation 
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Introduction 
Brugada syndrome (BrS) is a distinct form of idiopathic ventricular fibrillation 
(VF).BrS is characterized by a unique electrocardiogram (ECG) pattern consisting of a 
right bundle branchblock-like morphology and ST-segment elevation in precordial leads. 
Results of many studies(1-10)have suggested that patients with syncope, particularly 
patients with a spontaneous type1 ECG pattern, have a significant risk ofsudden cardiac 
death (SCD)or VF.In the remaining population of asymptomatic subjects, the risk is 
lower, but not negligible(1,5). Therefore, assessment ofthe risk of SCD and VF in 
patients with Brugada type ECGis clinically important, especially when sporadic cases 
are detected during routine medical check-ups. 
Many markersfor development of VFin BrS have been reported, including clinical 
markers ofa family history of sudden cardiac death (11), syncope with nonprodromal 
episodes(12),episodes of paroxysmal atrial fibrillation (PAF)(13), electrocardiographic 
markers of spontaneous type1 ECG pattern, existence of late potential (14), fragmented 
QRS (f-QRS)(15),T-wave alternans after sodium channel blocker injection 
(16),aninfero-lateral early repolarization (ER) pattern(17,18), agenetic marker of 
SCN5A, a gene encoding the cardiac sodium channel(19),electrophysiological markers 
of VF inducibility by programmed electrical stimulation, abnormal restitution 
properties,and ventricular effective refractory period <200ms(20). However, the 
relationship of these markers and the usefulness of their combination have not been 
sufficiently examined. 
In this study, we examinedrisk markers, with a focus on noninvasive surface 
ECGmarkers categorized by depolarization and repolarization abnormalities, and 
attempted to improve the accuracy of prediction and classification of high- and low-risk 
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BrSpatients. 
 
Methods 
Patient population and clinical data collection 
We retrospectively analyzeddata from246consecutive patients(236 males; mean 
age,47.6±13.6 years) with Brugada type ECG in Okayama University Hospital. All 
patients showed a typical ECG “Brugada pattern” with or without a sodium channel 
blocker (pilsicainide), which was defined previously(11). Informed consent was 
obtained from all subjects, andclinical data, including data on age, sex, family history of 
SCD (less than 45 years old), history of syncopal episodes,history of VF episodes, and 
VF induction during electrophysiological (EP) studywere obtained from patient 
records.Follow-up data defined that the start of follow-up was taken as first visit,and the 
end of follow-up was set to death, arrhythmic events, or the last visit. 
Electrocardiographic measurements 
Standard 12-lead ECGs were recorded inthe same way and were evaluated for the 
RRinterval, PQ interval, QRS width, QT interval, ST level at the J point,and number of 
positive spikes within the QRS complex in leads V1through V3.A spontaneous type1 
pattern was defined as documentation by ECG of a type 1 pattern in the absence of class 
I anti-arrhythmic drugs. The presence of a late potential was evaluated by a 
signal-averaged ECG (ART 1200 EPX, noise level <0.3μV, and high-pass filtering of 
40 Hz with a bidirectional 4-pole Butterworth).A late potential was positive when the 
following two criteria were met: root-mean-square voltage of the terminal 40ms in the 
filtered QRS complex <20μV and a duration of low-amplitude signals <40μV in the 
terminal filtered QRS complex >38ms(21). 
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The presence of f-QRS was defined as an abnormal fragmentation within the QRS 
complex as ≥four spikes in one or ≥eight spikes in all of the leads V1, V2, and V3 as 
described previously(15)(Figure 1A). 
Aninfero-lateral ER pattern was defined as an elevation of the J point in at least two 
consecutive leads. The amplitude of the J wave or J-point elevation had to be at least 1 
mm above the baseline level, either as QRS slurring or notching in the inferior lead (II, 
III, and aVF), lateral (I, aVL, and V4–V6) lead, or both as described 
previously(17,18,22-25)(Figure 1B). 
We divided the patients into thedepolarization abnormality (PQ interval >200ms,QRS 
width≥120ms, positive late potential, and f-QRS)group andtherepolarization 
abnormality (QT prolongationand infero-lateral ER pattern) group. 
EP study 
After obtaining written informed consent from patients, an EP study was performed as 
described previously(1,26) in all patients.The criterion for the induction of 
ventriculararrhythmia was induction of sustained polymorphic ventriculartachycardia or 
VF by programmed electrical stimulation from the right ventricularapex, right 
ventricular outflow tract, or left ventricle with amaximum of threeextrastimuli at two 
cycle lengths. 
Gene mutation analysis of SCN5A 
This study was performed in compliance with guidelines for human genome studies of 
the Ethics Committee of Okayama University as described previously(13). In brief, all 
exons of SCN5A were amplified by polymerase chain reaction from DNA isolated from 
peripheral leukocytes of the patients. Genomic DNA was extracted from peripheral 
blood leukocytes using a DNA extraction kit (Gentra, Minneapolis,Minnesota, USA) 
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and was stored at –30°C until use. Twenty-seven exons of the SCN5A gene were 
amplified with previously reported intronic primers(13). 
Statisticalanalysis 
Statistical analysis was performed using SPSS 17.0 for Windows (SPSS Inc, Chicago, 
IL, USA).Data are expressed as mean ± SD or median (IQR) values.Student’s t test was 
performed to test for statistical differences between two unpaired mean values, and 
categorical data and percentage frequencies were analyzed by the chi-square 
test.Inunivariate analysis, nine predictors were significantly associated with arrhythmic 
events. Multivariate analysis using Cox proportional-hazards regression analysis 
estimated thosenine predictors and was performed in search of independent risk factors 
for arrhythmic events.This analysis was based on a stepwise algorithm, with the p value 
set at 0.05 for entering and 0.1for exclusion.The effects of ER and f-QRS on arrhythmic 
events during the follow-up period were evaluated using the log-rank test and were 
described using a Kaplan Meier curve. P<0.05 was considered statistically significant. 
 
Results 
Patients’ characteristics 
Baseline patients’ characteristics are summarized in Table 1. Sixty-ninepatients 
(28.0%) had anfamily history of SCD, 40 (16.3%) had history of syncopal episodes, and 
13 (5.3%) had history of VF episodes. Gene analysis showed that SCN5A 
genemutationwas present in 17 patients (13.8%). Spontaneous type1 ECG was observed 
in 156patients (63.4%). In theEP study, VF was induced in 71patients (45.8%), and 63 
of them (25.6%) had received ICD implantation. During the follow-up period of 
45.1±44.3months, fatal arrhythmic events occurred in 24 patients(23 appropriate ICD 
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shocks due to VF and onecardiac arrest duringsleep). 
 
Clinical/genetic/ECG parameters and cardiac events 
Clinical and genetic parameters were compared in BrS patients with and those without 
cardiac events during the follow-up period (Table2). PAF episodes (9/24, 37.5% versus 
35/222, 15.8%, P=0.013), ahistory of VF (9/24, 37.5% versus 4/222, 1.8%, P<0.001), a 
history of syncopal episodes (13/24, 54.2% versus 27/222, 12.2%, P<0.001), VF 
inducibility during EP study (17/24, 70.8% versus 54/131, 41.2%, P=0.007), and 
spontaneous type1 ECG (22/24, 91.7% versus 134/222, 60.4%, P=0.002) were observed 
more oftenin VF/SCD patients than in those without VF/SCD,butother parameters such 
as age, sex,family history of SCD, and SCN5A gene mutation were not different. 
Among the ECG parameters of depolarization abnormalities, QRS width≥120ms 
(8/24,33.3% versus 29/222, 13.1%, P=0.015),and f-QRS (20/24,83.3% versus 58/222, 
26.1%,P<0.001) were observed more oftenin patients with VF/SCD than in those 
without VF/SCD. Among the ECG parameters of repolarization abnormalities, 
aprolonged QTcinterval>440ms (7/24,29.2% versus 28/222, 12.6%, P=0.036) and 
infero-lateral ER pattern (8/24,33.3% versus 17/222, 7.7%, P<0.001) were observed 
moreoften in patients with VF/SCD than in those without VF/SCD. 
Multivariate analysis showed that the following four parameters were independent risk 
factors for arrhythmic events: f-QRS(hazard ratio, 5.21; 95% confidence interval [CI], 
1.69 to 16.13; P=0.004),infero-lateral ER pattern (hazard ratio, 2.87; 95% CI, 1.16 to 
7.14; P=0.023), a history of VF episodes (hazard ratio, 19.61; 95% CI, 4.12 to 90.91; 
P<0.001),and a history of syncopal episodes (hazard ratio, 28.57; 95% CI, 6.14 to 
142.86; P<0.001) (Table 2).  
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Patients’ characteristics withf-QRS 
In multivariate analysis, depolarization abnormalitiesof f-QRS were an independent 
risk factor for arrhythmic events. Therefore, clinical, genetic, and electrocardiographic 
data for patients with and those without f-QRS wereanalyzed again (Table 3). There 
were no significant differences in age, family history of SCD, and incidence of 
theSCN5A gene mutationbetween patients with and those without f-QRS. However, 
ahistory of syncopal episodes, a history of VF episodes, and VF inducibilityduring EP 
studywere more frequentlyobserved in patients with f-QRS than in those without 
f-QRS(P=0.002, 0.005, and0.002, respectively).PQ interval, QRS duration and QTc 
interval werelonger in patients with f-QRS than in those without f-QRS (P=0.037, 0.001, 
and 0.042, respectively), but the ER pattern was not different between the groups. 
Spontaneous type1 ECG and PAF episodes were more frequently observed in patients 
with f-QRS than in those without f-QRS (P<0.001and P=0.031, respectively). VF/SCD 
episodes during follow- up were more frequently observed in patients with f-QRS than 
in those without f-QRS (P<0.001). 
 
Patients’ characteristics with anER pattern 
In multivariate analysis, repolarization abnormality of the ER pattern was an 
independent risk factor for arrhythmic events. Therefore, clinical, genetic, and 
electrocardiographic data with and without an ER pattern wereanalyzedagain (Table 4). 
There were no significant differences in age, family history of SCD, incidence of 
SCN5A gene mutation, positive late potential, a history of syncopal episodes, f-QRS,and 
VF inducibility during the EP study. However, VF/SCD episodes during followup and a 
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history of VF episodeswere more frequentlyobserved in patients with ER than in those 
without ER (P=0.001 and 0.005, respectively). 
 
Follow-up data 
We next examined the follow-up data in patients with f-QRS and ER.Twenty-three 
patients developedVF, one patient died suddenly during sleep,possibly due to VF, and 
one patient died of a non-arrhythmic cause (pneumonia) during the follow-up period. 
Figure 2shows the results of Kaplan-Meier analyses of fatal arrhythmic events in 
patients with and those without f-QRS (Fig. 2A) oran ER (Fig. 2B) pattern. Patients 
with f-QRS or ER had a significantly worse prognosis than did patients without those 
parameters (P<0.001 and <0.001,respectively). 
Figure 3 shows results of the combination analysis of f-QRSand ERparameters. 
Patients with both f-QRS and ER parameters had a significantly higher frequency 
offatal arrhythmic events than did patients without both parameters (P<0.001). 
Moreover, patients with both f-QRS and ER parameters had a significantly higher 
frequency of arrhythmic events than did patients with f-QRS alone (P=0.045,Fig.3). 
 
Discussion 
The present study showed that the combination of f-QRSand infero-lateral ER pattern 
was associated withdevelopment of VFin BrS patients. Additionally,the combination of 
f-QRS with ER (depolarization and repolarization abnormalities)was useful for 
identifying high- and low-riskBrS patients. 
High-risk clinical parametersof VF development 
Previous studies have reported that syncopal episodes (especially in patients with 
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prodrome), a history of VF, and a family history of sudden death are associated with VF 
events in BrS patients(3,4,12,20,27-29). In our study, we also observed that syncopal 
episodes and a history of VF were independent predictors of later VF events. These 
patients were symptomatic patients, and therefore it is reasonable to classify them as 
high-risk patients. However, more patients have no symptoms with electrocardiographic 
evidence of Brugada syndrome (asymptomatic Brugada patients). A recent 
studysuggested that these asymptomatic patients have a better prognosis, but not 
negligible (1,5). Therefore, simple risk assessment for these asymptomatic Brugada 
patients is clinically important, especially when sporadic cases are detected during 
routine medical check-ups. 
Repolarization abnormalities in BrS 
Many clinical data support the importance of repolarization abnormalities for VF 
development, such as T-wave alternans after sodium channel blocker injection (16), and 
ST elevation after exercise (30) or full-stomach status(31) . 
An ER pattern is considered to be a benign ECG phenomenon affecting 2–5% of the 
general population and is most commonly observed in young men (32,33). Recently, an 
ER pattern has been shown as an additional risk marker for VF development, especially 
in infero-lateral leads, in patients with BrS(17,18). Our finding that repolarization 
abnormalitieswere independently associated with VF development is in agreement with 
these previous findings. 
Depolarization abnormalities in BrS 
In addition to repolarization abnormalities, recent observations have suggested that VF 
development in BrS is associated with conduction disturbances, such as prolongation of 
the PQ interval (34), a wide QRS complex (35), a positive late potential (36), and 
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f-QRS (15,20). A recent study showed that f-QRS is the strongest predictor of VF 
development in BrS(20). The usefulness of f-QRS for identifying patients at high risk 
for various cardiac diseases, including cardiac sarcoidosis, arrhythmogenic right 
ventricular cardiomyopathy, and acute coronary syndrome (37), has been reported. Our 
finding that f-QRS (depolarization abnormality) was an independent predictor for VF 
development is in agreement with those results. We also found that f-QRS was 
associated with other depolarization abnormalities, such as a prolonged PQ and QRS 
interval,indicating that depolarization abnormalities in the atrium and ventricle are an 
important factor for development of VF in BrS.   
A QRS interval in lead V2 ≥120 ms was found to be a possible predictor of 
life-threatening ventricular arrhythmia and/or syncope. Prolonged QRS duration as 
measured on a standard 12-lead ECG has been shown to be associated with ventricular 
arrhythmia (35).Additionally,a prolonged QRS duration in precordial leads is prominent 
in symptomatic patients, suggesting that delayed conduction of the ventricle 
(depolarization) is important (29,38). However, in multivariate analysis in our study, 
there were no significant differences in wide QRS complex between patients with and 
those without VF/SCD. 
Combination of depolarization and repolarization abnormalities 
In this study, Kaplan-Mayer analyses showed that the combination of f-QRS 
(depolarization abnormality) and ER (repolarization abnormality) is useful for 
predicting VF events in patients with BrS. Recently, f-QRS was reported to be an 
important marker for the development of VF (Torsade de pointes) in patients with 
acquired long QT syndrome (typical repolarization abnormality disease) (39), indicating 
thatthe combination of depolarization and repolarization is important for the 
13 
 
development of lethal arrhythmia. We also found that VF seldom developed in patients 
without any abnormalities during the follow-up period in this study, suggesting that 
low-risk BrS patients could also be identified using these markers. 
We also investigated the clinical/electrocardiogaphic characteristics of 
depolarizationand repolarization abnormalities. Interestingly, there were many 
differences between the groups (Tables 34). Patients with f-QRS had more 
depolarization abnormalities than those without f-QRS, such as prolonged PQ and QRS 
intervals. In contrast, patients with an ER pattern had no differences in these markers, 
suggesting that the genesis of each of these abnormalities is intrinsically different. 
 
Clinical implications  
BrSis a heterogeneous disease. Therefore, the mechanism of VF development differs 
in each patient. Our resultssuggest that the combination of depolarization and 
repolarization abnormalities (f-QRS, and ER pattern) enables identification of high- and 
low-risk patients with BrS. In the clinical setting, VF induction during EP study is still 
considerable to decide the ICD implantation. Thus we think we should recommend EP 
study in a patient with f-QRS and ER pattern even in an asymptomatic case, or we do 
not need EP study in an asymptomatic case of neither f-QRS nor ER pattern. 
 
Limitations 
This study has several limitations. First, the ECG features of ER and other ECG 
markers are dynamic, andthus the true prevalence of this coexistence isdifficult to 
evaluate. Second, we analyzed only the coding regions of SCN5A for mutations in this 
study, and the possibility of mutations occurring in regions of the gene other than 
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coding regions or other gene mutations cannot be excluded. Third, Nishii et al. reported 
that SCN5Agene mutations are associated with early and frequent VF recurrence(19), 
but not with initial VF episodes. In our study, we did not find a significant difference. 
Therefore, further studies on this issue are required.Fourth, this study was a 
retrospective study.A prospective study to estimate risk factors of BrS is required.And 
the last, there were a small number of endpoints making it difficult to identify unique 
predictors in a multivariate model reliably. 
 
Conclusions 
Our study shows that ER and f-QRS are independent risk factors for arrhythmic events 
in patients withBrS. Patients with both ER and f-QRS have a significantly higher 
frequency of arrhythmic events than do patients who haveneither ER nor f-QRS. 
Furthermore, when there is neither ER nor f-QRS, arrhythmic events are small. 
Clinically, this study shows that the combination of f-QRS (marker of depolarization 
abnormality) and ER (marker of repolarization abnormality) is useful for estimating the 
incidence of VF in patients withBrS.  
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Figure legends 
Figure1: Representative ECGs of fragmented QRS (f-QRS) and early repolarization 
(ER). (A) Fragmented QRS (f-QRS) was observed in lead V2. Note that there are four 
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spikes (arrows) in this lead. (B) Early repolarization (ER) pattern in the inferior leads.  
Note that J-point elevation above the baseline (>1mm) can be seen in leads III and  
aVF. 
Figure2: Kaplan-Meier analysis of VF/SCD events.  
Ventricular fibrillation (VF)/ sudden cardiac death (SCD) events were observed often in  
the presence of (A) fragmented QRS (f-QRS), and (B) early repolarization (ER). 
Figure3: Kaplan-Meier analysis of VF/SCD events. 
Ventricular fibrillation (VF)/ sudden cardiac death (SCD) events were observed often 
inthe combination of depolarization (f-QRS) and repolarization abnormalities 
(ERpattern).  



Table1 . Patients' Characteristics
Male/Female      236/10
Age, yrs 47.6±13.6
Mean follow up period, months 45.1±44.3
History of syncopal episode (%) 40        (16.3%)
History of VF episode (%) 13          (5.3%)
Family history of SCD (%) 69        (28.0%)
Paroxysmal AF (%)     44        (17.9%)
Spontaneous type-1 ECG (%)  156        (63.4%)
ER pattern (%)  25        (10.2%)
fragmented QRS (%)  78        (31.7%)
Positive LP  (%) 166/235      (70.6%)
SCN5A gene mutation (%) 17/123      (13.8%)
VF induction during EP study (%) 71/155      (45.8%)
ICD implantation (%)  63        (25.6%)
VF or SCD event during follow-up period (%  24          (9.8%)
Values are mean ±SD or number of patients.
and VF=ventricular fibrillation.
SCN5A =pore-forming region of the human cardiac sodium channel;
AF=atrial fibrillation; ECG=electrocardiogram; EP=electrophysiology; 
ER=early repolarization; ICD=implantable cardioveter defibrillator; 
LP=late potential; SCD=sudden cardiac death; 
VF/SCD (+) VF/SCD(-) Odds Ratio 95%CI
Clinical/genetic parameters
Number of patients (male/femal 23/1  213/9 1.029 0.125-8.490
Age, yrs  47 (15) 48 (21)
History of syncopal episode (%) 13   (54.2) 27   (12.2) 8.535 3.477-20.955
History of VF episode(%) 9    (37.5) 4      (1.8) 32.700 .012-118.645
Paroxysmal AF (%) 9    (37.5) 35   (15.8) 3.206 1.301-7.899
Family history of SCD (%) 8    (33.3)  61   (27.5) 1.320 0.537-3.241
SCN5A  gene mutation (%) 4/23 (17.4) 3/100 (13.0) 1.409 0.414-4.799
VF induction during EP study 17/24 (70.8)54/131(41.2) 3.463 1.344-8.293
Spontaneous type-1 ECG (%) 22   (91.7) 134  (60.4) 7.224 1.657-31.491
Depolarization parameters
Positive f-QRS (%) 20   (83.3)  58   (26.1) 14.138 4.638-43.093
Positive LP (%) 20/24 (83.3)46/211(69.2) 2.226 0.732-6.772
PQ >200msec (%) 8    (33.3) 40   (18.0) 2.275 0.911-5.681
QRS ≧120msec (%) 8    (33.3) 29   (13.1) 3.328 1.307-8.469
Repolarization parameters
ER pattern　(%) 8    (33.3) 17    (7.7) 6.029 2.258-16.103
QTc >440msec (%) 7    (29.2) 28  (12.6) 2.853 1.087-7.490
Table2. Characteristics of patients with and without VF/SCD during follow-up p
AF=atrial fibrillation; CI=confidence interval; ECG=electrocardiogram;EP=electrophysiology; ER=
LP=late potential; SCN5A =pore-forming region of the human cardiac sodium channel; VF=ventricu
Values are mean ± SD, median (IQR), or number of patients.
Univariate Analysi
p Value Hazard Ratio 95％CI p Value
0.649
0.835
<0.001 28.5716.135-142.857 <0.001
<0.001 19.608 4.115-90.909 <0.001
0.013 0.306
0.554
0.396
0.007 0.562
0.002 0.114
<0.001 5.208 1.689-16.129 0.004
0.150
0.069
0.015 0.908
<0.001 2.874 1.160-7.143 0.023
0.036 0.608
pariod
=early repolarization; f-QRS = fragmented QRS; 
ular fibrillation.
is Multivariate Analysis
f-QRS(+) f-QRS(-)
Number of patients (male/female) 76/2 160/8
Age, yrs 48.5± 12.9 47.2±14.0
History of syncopal episode (%)       21     (26.9)      19    (11.3)
History of VF epsode (%)      9     (11.5)       4       (2.4)
Paroxysmal AF (%)      20     (25.6)      24     (14.3)
Family history of SCD (%)      23     (29.5)      46     (27.4)
SCN5A  gene mutation (%)     9/43    (20.9)     8/80    (10.0)
VF induction during EP study (%)    34/54    (63.0)     37/101  (35.9)
ICD implantation (%)      37     (47.4)      26     (15.5)
VF or SCD event during follow-up (%) 20     (25.6) 4       (2.4)
Duration of PQ interval, msec 184±29 176±26
Duration of QRS complex, msec 108 (24) 100 (17)
Duration of QTc interval, msec 419±30 411±24
Amplitude at J point V1, mV 0.12 (0.15) 0.11 (0.10)
Amplitude at J point V2, mV 0.21 (0.21) 0.201 (0.17)
Amplitude at J point V3, mV 0.13 (0.12) 0.12 (0.12)
Positive ER pattern (%)       9      (11.5)     16     (9.5)
Spontaneous type-1 ECG (%)     63     (80.8)     93   (55.4)
Positive LP (%)    59/75    (78.7)    107/160(66.9)
VF=ventricular fibrillation
Table3. Characteristics of patients with and without f-QRS
Clinical/genetic parameters
ECG parameters
Values are mean ±SD, median (IQR), or number of patients.
SCD=sudden cardiac death; SCN5A=pore-forming region of the human cardiac sodium
AF=atrial fibrillation; ECG=electrocardiogram; EP=electrophysiology; ER=early repo
 f-QRS=fragmented QRS; ICD=implantable cardioveter defibrillator; LP=late potencia
p Value
0.511 
0.514 
0.002 
0.005 
0.031 
0.732 
0.094 
0.002 
<0.001 
<0.001 
0.037 
0.001 
0.042 
0.347 
0.468 
0.929 
0.653 
<0.001 
0.064 
m channel; 
olarization; 
al; 
ER(+) ER(-)
Number of patients, men/women 23/2 213/8
Age, yrs 43 (23) 49 (20)
History of syncopal episode (%)     5      (20.0) 35     (15.8)
History of VF episode (%)     5      (20.0)     8       (3.6)
Paroxysmal AF (%)     3      (12.0)     41     (18.6)
Family history of SCD (%)     7      (28.0)     62     (28.1)
SCN5A gene mutation (%)  2/15   (13.3)   15/108 (13.9)
VF induction during EP study (%)  9/21   (42.9)   62/134 (46.3)
ICD implantation (%)    13     (52.0)     50     (22.6)
VF or SCD event during follow-up (% 8      (32.0) 16       (7.2)
Duration of PQ interval, msec 190±34 177±26
Duration of QRS complex, msec 99 (17) 104 (20)
Duration of QTc interval, msec 405±27 414±26
Amplitude at J point V1, mV 0.14 (0.14) 0.11 (0.12)
Amplitude at J pointV2, mV 0.21 (0.25) 0.20 (0.16)
Amplitude at J pointV3, mV 0.17 (0.17) 0.12 (0.11)
Positive f-QRS (%)      9      (36.0)       69     (31.2)
Spontaneous type 1 ECG (%)    14     (56.0)      142    (64.3)
Positive LP (%)  17/23   (73.9)   149/212 (70.3)
SCN5A=pore-forming region of the human cardiac sodium channel; VF=ventricular fibri
f-QRS=fragmented QRS; ICD=implantable cardioveter defibrillator; LP=late potencial; 
SCD=sudden cardiac death; 
Table4. Characteristics of patients with and without ER
Clinical/genetic parameters
ECG parameters
Values are mean ±SD, median (IQR), or number of patients.
AF=atrial fibrillation; ECG=electrocardiogram; EP=electrophysiology; ER=early repolar
p Value
0.269 
0.820 
0.383 
0.005 
0.584 
0.995 
1.000 
0.770 
0.001 
0.001 
0.053 
0.335 
0.097 
0.306 
0.505 
0.069 
0.653 
0.417 
0.717 
illation
rization;  
